Arcutis Biotherapeutics (ARQT) investor relations material

Company overview and product portfolio

• Focuses on inflammatory skin conditions with four approved ZORYVE products for psoriasis, atopic dermatitis, and seborrheic dermatitis, plus a novel biologic in phase I trials.

• ZORYVE products include creams and foam, with approvals for both adult and pediatric populations, and ongoing label expansion efforts.

• Eight approvals achieved in less than four years, with further pediatric and infant indications expected soon.

Commercial performance and financial outlook

• Achieved $127.5 million in Q4 product revenues, representing 85% year-over-year growth in net sales.

• 2026 product revenue guidance raised to $480–$495 million, driven by Q4 trajectory and strategic investments.

• Positive cash flow began in Q4, with plans to reinvest in sales force expansion and promotional activities.

• Gross-to-net remains stable in the 50% range, supported by strong payer coverage and strategic pricing.

Market dynamics and growth drivers

• Holds 50% share of the advanced topical therapy market, with 90%+ of treated patients using topicals.

• Foam SKU is a major growth driver, accounting for over half of total volume and offering unique benefits for scalp and body treatment.

• Sales force expanded from 130 to 160 reps to optimize reach among mid-tier dermatologists.

• Building a primary care and pediatric sales team to capture opportunities outside dermatology, especially as pediatric indications expand.